Yocca Frank 4
4 · BioXcel Therapeutics, Inc. · Filed Mar 16, 2026
Research Summary
AI-generated summary of this filing
BioXcel (BTAI) CSO Frank Yocca Converts 68 RSUs
What Happened
Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics (BTAI), converted a total of 68 restricted stock units (RSUs) into common shares on March 14–15, 2026 (33 shares on Mar 14; 35 shares on Mar 15). The filing shows matching disposals for the same share counts at $0.00, so no cash proceeds were reported. The transaction type is listed as "M" (exercise/conversion of a derivative security).
Key Details
- Transaction dates: March 14, 2026 (33 shares) and March 15, 2026 (35 shares). Total converted: 68 shares.
- Prices/values reported: Acquisitions show price N/A; disposals reported at $0.00, total proceeds $0.00.
- Filing: Reported on Form 4 filed March 16, 2026 for transactions on March 14–15, 2026 (timely filing).
- Shares owned after the transaction: not specified in the provided excerpt.
- Relevant footnotes:
- F1: Each RSU represents a contingent right to receive one share of common stock.
- F2/F3: RSUs were granted March 14, 2022 (521 RSUs) and March 15, 2023 (562 RSUs) with standard time-based vesting (25% at first anniversary, then 6.25% quarterly thereafter).
Context
- Code M denotes exercise or conversion of a derivative; here it reflects RSUs vesting and converting into shares. The matching disposals at $0.00 are commonly how filings record shares surrendered upon conversion (often to satisfy tax withholding), but the filing excerpt does not specify the reason for the $0.00 disposals.
- These are not open-market purchases or sales intended as market bets; they reflect compensation vesting mechanics rather than an express buy/sell decision.
Insider Transaction Report
Form 4
Yocca Frank
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-14+33→ 6,485 total - Exercise/Conversion
Common Stock
[F1]2026-03-15+35→ 6,520 total - Exercise/Conversion
Restricted Stock Units
[F1][F2]2026-03-14−33→ 97 total→ Common Stock (33 underlying) - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-03-15−35→ 247 total→ Common Stock (35 underlying)
Footnotes (3)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
- [F3]On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Signature
/s/ Richard Steinhart, as Attorney-in-Fact for Frank Yocca, Ph.D|2026-03-16